BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 9240645)

  • 1. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
    Calais G; Dorval E; Louisot P; Bourlier P; Klein V; Chapet S; Reynaud-Bougnoux A; Huten N; De Calan L; Aget H; Le Floch O
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):769-75. PubMed ID: 9240645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
    Gaspar LE; Qian C; Kocha WI; Coia LR; Herskovic A; Graham M
    Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):593-9. PubMed ID: 9112458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
    Yorozu A; Dokiya T; Oki Y
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):271-5. PubMed ID: 10487545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy.
    Wang Q; Li T; Liu H; Jia X; Liu B; Wan X; Lang J
    Radiat Oncol; 2014 Apr; 9():99. PubMed ID: 24774780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Gaspar LE; Winter K; Kocha WI; Coia LR; Herskovic A; Graham M
    Cancer; 2000 Mar; 88(5):988-95. PubMed ID: 10699886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Curative treatment of non-metastatic esophageal cancer: concomitant chemoradiotherapy and high-dose-rate endoluminal curietherapy boost].
    Taieb S; Vaillant E; Pommier P; Bonvoisin S; Desseigne F; Morignat E; Gerard JP; Mornex F
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1048-54. PubMed ID: 10592877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
    Brunner TB; Rupp A; Melzner W; Grabenbauer GG; Sauer R
    Strahlenther Onkol; 2008 Jan; 184(1):15-22. PubMed ID: 18188518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
    Grigsby PW; Lu JD; Mutch DG; Kim RY; Eifel PJ
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):817-22. PubMed ID: 9652843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy of esophageal carcinoma.
    Poplin EA; Khanuja PS; Kraut MJ; Herskovic AM; Lattin PB; Cummings G; Gaspar LE; Kinzie JL; Steiger Z; Vaitkevicius VK
    Cancer; 1994 Aug; 74(4):1217-24. PubMed ID: 8055441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The combined radiochemotherapy of inoperable esophageal neoplasms: a feasibility study].
    Sola B; Airoldi M; Orecchia R; Rovea P; Fracchia F; Boidi Trotti A; Tessa M; Foco A; Oliaro A; Casadio C; Dei Poli M
    Radiol Med; 1996 Apr; 91(4):456-9. PubMed ID: 8643859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
    Damle S; Beitler JJ; Haynes H; Camacho M; Wolf E; Wadler S
    Am J Clin Oncol; 1999 Aug; 22(4):391-5. PubMed ID: 10440197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomas].
    Hennequin C; Salemkour A; Mal F; Lecomte T; Boudet MJ; Perniceni T; Gayet B; Maylin C; Raymond E
    Bull Cancer; 2001 Feb; 88(2):203-7. PubMed ID: 11257595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.